Macrophage News and Research

RSS

A macrophage is a type of white blood cell that surrounds and kills microorganisms, removes dead cells, and stimulates the action of other immune system cells.

Study: Blood cell growth factor improves effects of exercise in patients with peripheral artery disease

A blood cell growth factor can boost the effects of exercise in improving mobility for patients with peripheral artery disease, a clinical study has shown.

19 Nov 2013

Identifying 'sensome' of microglia could improve treatments for neurodegenerative disorders

Massachusetts General Hospital investigators have used a new sequencing method to identify a group of genes used by the brain's immune cells - called microglia - to sense pathogenic organisms, toxins or damaged cells that require their response.

15 Nov 2013

Researchers identify specific IRE1a inhibitor for rheumatoid arthritis treatment

Collaborating with researchers from the Northwestern University Feinberg School of Medicine in Chicago, a research team at Wayne State University's School of Medicine led by Kezhong Zhang, Ph.D., has contributed to an important discovery in the inflammatory stress mechanism and specific inhibitor for the treatment of rheumatoid arthritis.

13 Nov 2013

‘Pioneering’ non-invasive coronary plaque imaging revealed

Combined 18F-sodium fluoride positron emission tomography–computed tomography allows physicians to visualize high-risk or ruptured coronary atherosclerotic plaques in patients with myocardial infarction or stable angina, research shows.

12 Nov 2013

Stanford researchers receive $1.37M grant to study on immune systems of pediatric cancer patients

Kathleen Sakamoto, MD, PhD, and Irving Weissman, MD, of the Stanford University School of Medicine and Lucile Packard Children's Hospital, have received a $1.37 million grant from CureSearch for Children's Cancer to research the effects of an antibody that has been shown to be effective against human cancers in animal models.

5 Nov 2013

Patients with mutation in gene encoding CX3CR1 at higher risk of candidiasis

Candida albicans is one of the leading causes of hospital-acquired infections in immune compromised patients. The risk of both developing candidiasis and the clinical outcome of infection is variable among patients, and the host-dependent factors that contribute to patient susceptibility to C. albicans infection are poorly understood.

4 Nov 2013

NHMRC awards over $6M for Griffith University research projects

Griffith University research projects have been awarded just over $6m in research funding by the prestigious National Health and Medical Research Council.

28 Oct 2013

Researchers identify potential way to combat TB

Researchers have identified a potential way to manipulate the immune system to improve its ability to fight off tuberculosis.

24 Oct 2013

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced positive results from the Phase 1 portion of its Phase 1/1b study of defactinib (VS-6063) in combination with paclitaxel in patients with ovarian cancer that were presented at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

21 Oct 2013

Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs

...

18 Oct 2013

Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs

...

17 Oct 2013

Research findings point the way to new class of antibiotics for skin and heart infections

Researchers at NYU Langone Medical Center have discovered a new mechanism by which the deadly Staphylococcus aureus bacteria attack and kill off immune cells. Their findings, published today in the journal Cell Host & Microbe, explain a critical survival tactic of a pathogen that causes more skin and heart infections than any other microbe, and kills more than 100,000 Americans every year.

17 Oct 2013

Research shows inhibition of Rcan1 protein may reduce atherosclerosis in mice

Researchers of the Spanish research council (Consejo Superior de Investigaciones Cient-ficas, CSIC) and the Centro Nacional de Investigaciones Cardiovasculares (CNIC) have discovered that inhibiting the protein Rcan1 in mice reduces the burden of atherosclerosis, one of the commonest cardiovascular diseases.

16 Oct 2013

New approach could help identify specific gene mutations linked to increased disease risk

Researchers at the University of California, San Diego School of Medicine have developed a new way to parse and understand how special proteins called "master regulators" read the genome, and consequently turn genes on and off.

13 Oct 2013

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, announced today that it has initiated a Phase 2 clinical trial to evaluate PRM-151, its lead product candidate, in patients with myelofibrosis.

10 Oct 2013

Newly discovered compound could be developed as antifungal drug to treat fungal infections

On a molecular level, you have more in common with shower curtain mold or the mushrooms on your pizza than you might think. Humans and fungi share similar proteins, a biological bond that makes curing fungal infections difficult and expensive.

7 Oct 2013

Research deals with important issues in the field of urolithiasi

A balance between the activation of the inflammatory macrophages and suppression of the anti-inflammatory macrophages in the kidney may play a pivotal role in kidney stone formation. These macrophage-derived mediators may have potential as biomarkers to reflect the urinary stone risk, according to a new study from Japan, which was recently presented at the recent 2nd Meeting of the EAU Section of Urolithiasis and received Clinical Research Award.

2 Oct 2013

Researchers develop new approach to combat tubercle bacillus

A new approach to combating the tubercle bacillus, the microorganism that kills some 1.5 million people in the world each year, has been developed by a French-British team including scientists from CNRS, Inserm, the Institut Curie and Université Toulouse III - Paul Sabatier.

2 Oct 2013

AMGEN announces additional results from talimogene laherparepvec Phase 3 trial

AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).

30 Sep 2013

Psoriasis and the nervous system: an interview with Dr Nicole Ward, Case Western Reserve University

The prevalence of skin disease exceeds that of obesity, hypertension or cancer. One in three individuals in the United States suffers with a skin disease, with ~2-3% of the American population suffering from psoriasis.

27 Sep 2013

Macrophage News and Research

Further Reading

Study: Blood cell growth factor improves effects of exercise in patients with peripheral artery disease

Identifying 'sensome' of microglia could improve treatments for neurodegenerative disorders

Researchers identify specific IRE1a inhibitor for rheumatoid arthritis treatment

‘Pioneering’ non-invasive coronary plaque imaging revealed

Stanford researchers receive $1.37M grant to study on immune systems of pediatric cancer patients

Patients with mutation in gene encoding CX3CR1 at higher risk of candidiasis

NHMRC awards over $6M for Griffith University research projects

Researchers identify potential way to combat TB

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs

Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs

Research findings point the way to new class of antibiotics for skin and heart infections

Research shows inhibition of Rcan1 protein may reduce atherosclerosis in mice

New approach could help identify specific gene mutations linked to increased disease risk

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

Newly discovered compound could be developed as antifungal drug to treat fungal infections

Research deals with important issues in the field of urolithiasi

Researchers develop new approach to combat tubercle bacillus

AMGEN announces additional results from talimogene laherparepvec Phase 3 trial

Psoriasis and the nervous system: an interview with Dr Nicole Ward, Case Western Reserve University

Microbiology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News